Lilly’s weight loss drug reduces diabetes risk in overweight patients
Eli Lilly’s weight-loss drug Zepbound dramatically reduces the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the drug’s maker said Tuesday.
ENTRADAS POPULARES
Putin may discuss Ukraine peace deal with Trump
noviembre 22, 2024
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
TRANSMISIÓN EN VIVO